Clinical trials: Antibody
Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia, in Relapse
Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia
This Phase 1 Study is an open-label, non-randomized, dose escalation, safety, efficacy, pharmacokinetic, and pharmacodynamic evaluation study of INA03 administered as a single agent IV infusion every 2 weeks to patients ≥18 years…
- Conditions
- Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukaemia Recurrent
- Trial name
- INA03 (NCT03957915)
- Testing
- INA03 administration
- Where
- 3 sites in France
- Volunteers
- 33 people
- Sponsor
- Institut Paoli-Calmettes
Advanced Solid Tumor
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
- Trial name
- BiPAVE-001 (NCT06635785)
- Testing
- AI-081
- Where
- 21 sites in United States
- Volunteers
- 387 people
- Sponsor
- OncoC4, Inc.
Ovarian Cancer
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer
This Phase 3 study will be conducted in different countries around the world with up to approximately 602 participants. The purpose of this study is to evaluate how well Rina-S alone or in combination with an approved, standard…
- Trial name
- RAINFOL™-10 (NCT07859215)
- Testing
- Rina-S, Bevacizumab
- Volunteers
- 602 people
- Sponsor
- Genmab
HER2 + Breast Cancer
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer
- Trial name
- NCT07294508
- Testing
- HLX87 + HLX22, HLX87 + Pertuzumab, T-Dxd + Pertuzumab
- Where
- China
- Volunteers
- 706 people
- Sponsor
- Shanghai Henlius Biotech
Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses.
- Trial name
- NCT00168740
- Testing
- rituximab
- Where
- 31 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Biogen
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD).
- Trial name
- BLISSc-ILD (NCT05878717)
- Testing
- Belimumab
- Where
- 134 sites in United States, Argentina and 16 more
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Migraine
Predictive Role of MIDAS Reduction at 3 Months for Erenumab Treatment
In 2021, the Italian Medicines Agency approved reimbursement of monoclonal antibodies targeting the CGRP pathway (CGRP-mAbs) as preventive therapies for patients with high frequency and chronic migraine (CM).
- Trial name
- Ere-MIDAS (NCT05442008)
- Testing
- Erenumab 70/140 mg s.c.
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
Advanced Solid Tumor, NSCLC
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
- Trial name
- MICA (NCT05117476)
- Testing
- CLN-619, Pembrolizumab, Paclitaxel
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 440 people
- Sponsor
- Cullinan Therapeutics Inc.
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
COVID-19 Pandemic, Transplantation, Kidney
Seroprevalence of the Anti-SARS-CoV-2 Antibodies (Causing COVID-19) in Kidney Transplant Recipients in Severely Affected Region
Goal of this study is to evaluate the seroprevalence of anti-SARS-CoV-2 antibodies in patients after kidney transplantation who are one of the risk groups for the severe course of the infection and map the progression of the…
- Trial name
- SECOVtx (NCT04874740)
- Testing
- No intervention
- Where
- Czechia
- Volunteers
- 300 people
- Sponsor
- University Hospital Ostrava
Wegener's Granulomatosis, Churg-Strauss Syndrome
Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides
The Systemic Necrotizing Vasculitides (SNV) encompass a group of rare diseases which include Wegener's Granulomatosis (WG), Churg-Strauss Syndrome (CSS), Microscopic polyangiitis (MPA)and Polyarteritis nodosa (PAN).
- Conditions
- Wegener's Granulomatosis, Churg-Strauss Syndrome, Microscopic Polyangiitis, Polyarteritis Nodosa
- Trial name
- NCT00751517
- Testing
- Methotrexate, Cyclophosphamide
- Where
- Italy
- Sponsor
- University of Parma
Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
This study is an open-label, single-arm, prospective, multicenter, phase I/II clinical trial. It adopts the two-stage optimal design proposed by Bryant and Day to investigate the efficacy, safety, and in vivo pharmacokinetic…
- Trial name
- NCT07324889
- Testing
- CD19/BCMA CAR-T
- Volunteers
- 24 people
- Sponsor
- Yihao Wang
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Chronic inflammatory demyelinating polyradiculoneuropathy is a diffuse multifocal autoimmune disorder of the peripheral neuron, affecting 1 to 9 in 100,000 people.
- Trial name
- SW_CIDP (NCT04529291)
- Testing
- Group with walking disorder, Group without walking disorder
- Sponsor
- Fondation Hôpital Saint-Joseph
Idiopathic Inflammatory Myopathies, ANCA-Associated Vasculitis
Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
This is an open-label, investigator-initiated clinical trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with refractory IIM and AAV.
- Trial name
- NCT06986018
- Testing
- RD06-04 Cell Injection Infusion
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Peking University People's Hospital
Urothelial Cancer, Metastatic Urothelial Carcinoma
Sacituzumab Govitecan Plus EV in Metastatic UC
Phase I of this research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin can be safely combined in the treatment of metastatic urothelial carcinoma (mUC).
- Conditions
- Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder Cancer
- Trial name
- NCT04724018
- Testing
- Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Dana-Farber Cancer Institute
Primary Immune Deficiency Disorder, Common Variable Immunodeficiency
The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease
This aim of this research project is to determine if low to moderate level exercise can have an impact on stress, fatigue, and quality of life for individuals diagnosed with a primary immunodeficiency disease.
- Conditions
- Primary Immune Deficiency Disorder, Common Variable Immunodeficiency, Specific Antibody Deficiency, Hypergammaglobulinemia
- Trial name
- NCT03211689
- Testing
- Exercise Program
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Stockton University
Influenza
Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses
The purpose of this study is to assess in healthy subjects the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses of CR8020, a monoclonal antibody against influenza A viruses.
- Trial name
- NCT01756950
- Testing
- 2 mg/kg CR8020, 5 mg/kg CR8020, 15 mg/kg CR8020
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Alzheimer Disease
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3000 (NCT00667810).
- Trial name
- NCT00996918
- Testing
- Bapineuzumab 0.5 mg/kg, Bapineuzumab 1.0 m/kg
- Where
- 82 sites in Australia, Belgium and 15 more
- Volunteers
- 198 people
- Sponsor
- Pfizer
Infections, Meningococcal
Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations
This is Phase IV, Open label, Multicenter study. Subject's parents and/or legal guardian will be provided information about the trial. If interested and if eligible, they will then be asked to provide signed informed consent.
- Trial name
- NCT02446691
- Testing
- MenACWY
- Where
- 6 sites in South Korea
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Advanced Cancer
Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer
This study is designed to determine the safety and highest tolerated dose of anti-OX40 in patients with advanced cancer.
- Trial name
- NCT01644968
- Testing
- Cohort 1 anti-OX40, Cohort 2 anti-OX40, Cohort 3 anti-OX40
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Providence Health & Services
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.